C A Schiffer
Affiliation: Wayne State University
- Acute myeloid leukemia in adults: where do we go from here?C A Schiffer
Wayne State University School of Medicine, Division of Hematology Oncology, Karmanos Cancer Institute, Detroit, MI 48201, USA
Cancer Chemother Pharmacol 48:S45-52. 2001..It is likely, however, that future advances will be a consequence of a better understanding of the biology of leukemic stem cells, and issues related to such studies are discussed...
- A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemiaC A Schiffer
Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
Blood 95:2530-5. 2000..Blood. 2000;95:2530-2535)..
- World Health Organization and international prognostic scoring system: the limitations of current classification systems in assessing prognosis and determining appropriate therapy in myelodysplastic syndromesCharles A Schiffer
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
Semin Hematol 45:3-7. 2008..They are less helpful in guiding treatment decisions in individual patients and, unfortunately, provide little insight into the poorly understood biology of MDS. The merits and limitations of these classification systems are discussed...
- BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemiaCharles A Schiffer
Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
N Engl J Med 357:258-65. 2007
- Myelodysplasia: the good, the fair and the uglyCharles A Schiffer
Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R Street, 4HW CRC, Detroit, MI 48201, USA
Best Pract Res Clin Haematol 20:49-55. 2007..Further refinements of dose and schedule of administration are also under investigation...
- Molecular characterization of AML: a significant advance or just another prognostic factor?Charles A Schiffer
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, 4100 John R, Detroit, MI 48201, USA
Best Pract Res Clin Haematol 21:621-8. 2008....
- Diagnosis and management of refractoriness to platelet transfusionC A Schiffer
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
Blood Rev 15:175-80. 2001..There are a number of selection strategies which can be utilized and optimal patient management requires close cooperation and communication between clinicians and blood centers...
- Perspectives on the treatment of chronic phase and advanced phase CML and Philadelphia chromosome positive ALL(1)C A Schiffer
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, Detroit, MI 48201, USA
Leukemia 17:691-9. 2003..Conservative and aggressive treatments will be discussed and new molecular methods of monitoring cytogenetic response and their significance will also be reviewed...
- Signal transduction inhibition: changing paradigms in cancer careC A Schiffer
Barbara Ann Karmanos Cancer Center Institute, Wayne State University School of Medicine, Detroit, MI, USA
Semin Oncol 28:34-9. 2001....
- Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug developmentC A Schiffer
Karmanos Cancer Institute and the Division of Hematology/Oncology, Wayne State University School of Medicine, Detroit, MI 48201, USA
Leukemia 16:745-7. 2002
- Treatment of high-grade lymphoid malignancies in adultsC A Schiffer
Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI 48201, USA
Semin Hematol 38:22-6. 2001....
- Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical OncologyC A Schiffer
Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit MI, USA
J Clin Oncol 19:1519-38. 2001..VALIDATION: Five outside reviewers, the ASCO Health Services Research Committee, and the ASCO Board reviewed this document. SPONSOR: American Society of Clinical Oncology..
- Advances in MDSCharles A Schiffer
Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Mich, USA
Clin Adv Hematol Oncol 5:450-2. 2007
- Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5qAzra Raza
Rush University Medical Center, Chicago, IL, USA
Blood 111:86-93. 2008..Lenalidomide has clinically meaningful activity in transfusion-dependent patients with low- or int-1-risk MDS who lack the deletion 5q karyotypic abnormality...
- Improvement of pulmonary function with imatinib mesylate in bronchiolitis obliterans following allogeneic hematopoietic cell transplantationNavneet S Majhail
Biol Blood Marrow Transplant 12:789-91. 2006
- The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrationsAnwar N Mohamed
Department of Pathology and the Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
Clin Cancer Res 9:1333-7. 2003..2) or its variants in a review of 137 CML patients treated with imatinib mesylate (STI571). Clinically 13 patients were in chronic phase, 24 in accelerated phase, and 21 in blastic phase...
- Practical aspects of the treatment of chronic myelogenous leukemia with imatinib mesylateJeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Harper Hospital, 4 Brush South, 3990 John R, Detroit, MI 48201, USA
Curr Hematol Rep 2:57-64. 2003..The feasibility of combining imatinib with other agents also needs to be examined, as does the utility of molecular monitoring of response. Finally, developing methods to overcome resistance to imatinib is a looming challenge...
- The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatmentJeffrey A Zonder
Karmanos Cancer Institute, Wayne State University, Detroit, Michigan 48201, USA
Clin Cancer Res 9:2092-7. 2003..Some patients with chronic-phase or accelerated-phase CML either relapse after an initial response or are refractory to imatinib, prompting us to evaluate the efficacy of dose increase in such patients...
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 studyMoshe Talpaz
M D Anderson Cancer Center, Houston, Texas, USA
Blood 99:1928-37. 2002..Orally administered imatinib is an effective and well-tolerated treatment for patients with CML in accelerated phase. A daily dose of 600 mg is more effective than 400 mg, with similar toxicity...
- A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemiasOliver G Ottmann
Medizinische Klinik III Abteilung Haematologie, Johann Wolfgang Goethe Universitat, 60590 Frankfurt, Germany
Blood 100:1965-71. 2002..Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib...
- Chronic lymphocytic leukemia presenting in association with aplastic anemiaJeffrey A Zonder
Division of Hematology Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
Am J Hematol 71:323-7. 2002..Possible humoral and cellular autoimmune mechanisms are examined as possible causes of marrow aplasia in this setting...
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II studyCharles L Sawyers
Department of Medicine and Molecular Biology Institute, University of California, Los Angeles, CA 90095, USA
Blood 99:3530-9. 2002..Additional clinical studies are warranted to explore the efficacy and feasibility of imatinib used in combination with other antileukemic drugs...
- Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group BLewis R Silverman
Division of Medical Oncology, Mount Sinai School of Medicine and Memorial Sloan Kettering Cancer Center, Box 1129, One Gustave L Levy Place, New York, NY 10029, USA
J Clin Oncol 20:2429-40. 2002..Supportive care is standard therapy. We previously reported that azacitidine (Aza C) was active in patients with high-risk MDS...
- Current treatment options and strategies for myelodysplastic syndromesSridhar Srinivasan
Wayne State University School of Medicine, Karmanos Cancer Institute, Division of Hematology Oncology, Detroit, MI 48201, USA
Expert Opin Pharmacother 9:1667-78. 2008..A number of scoring systems have been developed but they are of limited value in guiding individual patient treatment decisions...
- Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitorsTannu Sahay
Division of Hematology Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
Curr Opin Hematol 15:134-9. 2008..With high rates of complete cytogenetic response induced by imatinib and other tyrosine kinase inhibitors, exploring refinements in current methods of minimal residual disease monitoring is relevant...
- Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatmentAndreas Hochhaus
Medizinische Fakultaet Mannheim, University of Heidelberg, Mannheim, Germany
Blood 111:1039-43. 2008..5 years, compared with earlier time points. Imatinib continues to be an effective and safe therapy for patients with CP CML after failure of IFN...
- Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B studyAlice B Kornblith
Women s Cancers Program, Dana Farber Cancer Institute, Rm D1210, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 20:2441-52. 2002..The impact of azacytidine (Aza C) on the quality of life of 191 patients with myelodysplastic syndrome was assessed in a phase III Cancer and Leukemia Group B trial (9221)...
- Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup studyRobert E Martell
Geriatrics Research, Education and Clinical Center, Veterans Affairs Medical Center and Hematology/Oncology Division, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Cancer Chemother Pharmacol 50:37-45. 2002..0001). CONCLUSIONS: Patient age was not an independent risk factor for fludarabine-related toxicity, but CrCl(est) was associated with time to toxicity...
- Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both?Charles A Schiffer
J Clin Oncol 21:760-1. 2003
- Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011Vicki A Morrison
Section of Hematology Oncology, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
J Clin Oncol 20:3878-84. 2002..A series of patients enrolled onto an intergroup CLL trial were examined for this complication...
- Fifty years of clinical research by the leukemia committee of the cancer and leukemia group BRichard A Larson
Department of Medicine and Cancer Research Center, University of Chicago, Chicago, Illinois, USA
Clin Cancer Res 12:3556s-63s. 2006....
- Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasiaBruce D Cheson
Department of Hematology/Oncology, Georgetown University Hospital, Washington, DC, USA
Blood 108:419-25. 2006..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
- "Acute myelogenous leukemia like" translocations in CML blast crisis: two new cases of inv(16)/t(16;16) and a review of the literatureBhaumik B Patel
Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Internal Medicine, Division of Hematology-Oncology, Karmanos Cancer Institute, 4HW-4238, 4100 John R, Detroit, MI 48201, USA
Leuk Res 30:225-32. 2006....
- A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapyChin Y Liu
Department of Pharmacy, Karmanos Cancer Institute Harper University Hospital, Detroit Medical Center, Detroit, MI 48201, USA
Leuk Res 29:463-5. 2005..The levels remained below 4 mg/dL throughout the administration of chemotherapy for up to 96 h. Utilizing the guidelines resulted in a significant cost savings of 100,000 US dollars...
- Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011John C Byrd
Division of Hematology Oncology, Department of Medicine, The Ohio State University, Columbus, OH 43210, USA
Blood 105:49-53. 2005..Confirmation of these findings will require a prospective randomized trial comparing fludarabine and rituximab to fludarabine...
- All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocolMartin S Tallman
Northwestern University, Feinburg School of Medicine, Department of Medicine, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
Blood 100:4298-302. 2002..The improvement in outcome with ATRA in APL was maintained with long-term follow-up...
- Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid LeukemiaBruce D Cheson
Department of Hematology Oncology, Georgetown University, Lombardi Cancer Center, 3800 Reservoir Rd, NW, Washington, DC 20007, USA
J Clin Oncol 21:4642-9. 2003..Storage of viable blasts for correlative studies is important for future progress in the therapy of these disorders...